Virax Biolabs signs three distributors for ImmuneSelect in mainland China
The company's China subsidiary struck non-exclusive deals with AmyJet, Jiangsu Real-Gen and Zhixi to sell its research-use immune profiling products across six provinces.
Virax Biolabs Group Limited announced on October 29, 2026 that its China subsidiary, Shanghai Xitu Consulting Co., Ltd., signed non-exclusive distribution agreements with AmyJet Scientific Inc., Jiangsu Real-Gen Biotechnology Co., Ltd., and Zhixi (Shanghai) Biotechnology Co., Ltd. covering its ImmuneSelect research-use immune profiling products.1
ImmuneSelect is described as Virax's commercially available research-use-only immune profiling portfolio, which the company distinguishes from ViraxImmune, its in-development diagnostic platform.1 The new deals follow earlier sales activity in the region and sit alongside an existing arrangement; the company said the appointments build on initial sales already made through Virax's mainland China operations and add to a prior exclusive supply deal with Fosun Diagnostics spanning six Southeast Asian markets.1
Under the agreements, the three distributors will buy ImmuneSelect products from Virax for resale in their designated territories and customer groups, handling local sales, customer engagement and training, while Virax supplies the products along with documentation and technical support.1 The arrangements cover non-exclusive channels across Beijing, Shanghai, Hubei, Jiangsu, Anhui and Shandong, including biotech hubs such as Zhongguancun Life Science Park in Beijing, Zhangjiang Pharma Valley in Shanghai, BioBAY in Suzhou and BioLake in Wuhan.1
Each distributor has a distinct focus. AmyJet, founded in 2010 and based in Wuhan, is an established distributor of research reagents and lab technologies with relationships spanning more than 200 international life sciences suppliers, including makers of ELISpot assays and cellular immunology products.1 Jiangsu Real-Gen, founded in 2011 and headquartered in Suzhou, supplies research instruments, reagents and consumables in immunology, cell biology and molecular biology, with regional operations in Nanjing, Hefei and Jinan serving biopharmaceutical, cell therapy, academic and government lab customers.1 Zhixi is a Shanghai-based life sciences distributor under common ownership with Shanghai KEL Biotech.1
The initial commercial focus will be ELISpot assay plates and antigen-specific peptide pools for infectious disease, vaccine and cellular immunity research.1 Virax said the distributor model supports commercial expansion while limiting the need to build a larger direct sales organization.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.